ABSTRACT. To study the effect of antenatal indomethacin or nylidrin hydrochloride treatment on the fetal and neonatal ductus arteriosus and tricuspid valve function, 84 pregnant women with threatened premature birth between 22.9 and 34.0 wk gestation and 94 of their offspring born at 24.7 to 41.6 wk of gestation were studied by Doppler echocardiography. Forty-six women were treated with indomethacin and 38 with nylidrin. Both peak systolic and peak diastolic velocities in the ductus increased after administration of indomethacin and exceeded the corresponding velocities in the fetuses of the nylidrin group ( p = 0.0001). Ductal constriction occurred in 42 of 49 fetuses treated with indomethacin (86%). Tricuspid valve regurgitation (TR) was evident in 11 of 49 fetuses treated with indomethacin (22%). The mean gestational age of the fetuses with TR (30.0 wk) tended to be higher than those without TR (28.3 wk, p = 0.056). In the nylidrin group, no fetus had ductal constriction or TR. A significant increase in peak systolic velocity ( r = 0.54, p = 0.0001) and in peak diastolic velocity ( r = 0.46, p = 0.0001) in the ductus with advancing gestational age was demonstrated in the indomethacin group; however, in the nylidrin group, there was a less remarkable increase in peak systolic velocity ( r = 0.35, p = 0.04) and no increase in peak diastolic velocity ( r = 0.02, p = 0.93). In infants born at or before 35 wk gestation, incidences of both spontaneous closure and indomethacin-induced closure of ductus were similar in both study groups (p > 0.1). Ductal reopening tended to occur more frequently after indomethacin (17%) than after nylidrin (0%) administration ( p = 0.15). These findings indicate that: 1) the fetal ductus becomes more reactive to indomethacin with increasing gestational age; 2) TR tends to occur in fetuses with advanced gestational age; and 3) prenatal exposure of indomethacin does not decrease the need for patent ductus arteriosus treatment in premature infants. (Pediatr Res 33: 615-619, 1993) Abbreviations PDA, patent ductus arteriosus PDV, peak diastolic velocity PSV, peak systolic velocity RDS, respiratory distress syndrome TR, tricuspid valve regurgitation
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ABSTRACT. To study the effect of antenatal indomethacin or nylidrin hydrochloride treatment on the fetal and neonatal ductus arteriosus and tricuspid valve function, 84 pregnant women with threatened premature birth between 22.9 and 34.0 wk gestation and 94 of their offspring born at 24.7 to 41.6 wk of gestation were studied by Doppler echocardiography. Forty-six women were treated with indomethacin and 38 with nylidrin. Both peak systolic and peak diastolic velocities in the ductus increased after administration of indomethacin and exceeded the corresponding velocities in the fetuses of the nylidrin group ( p = 0.0001). Ductal constriction occurred in 42 of 49 fetuses treated with indomethacin (86%). Tricuspid valve regurgitation (TR) was evident in 11 of 49 fetuses treated with indomethacin (22%). The mean gestational age of the fetuses with TR (30.0 wk) tended to be higher than those without TR (28.3 wk, p = 0.056). In the nylidrin group, no fetus had ductal constriction or TR. A significant increase in peak systolic velocity ( r = 0.54, p = 0.0001) and in peak diastolic velocity ( r = 0.46, p = 0.0001) in the ductus with advancing gestational age was demonstrated in the indomethacin group; however, in the nylidrin group, there was a less remarkable increase in peak systolic velocity ( r = 0.35, p = 0.04) and no increase in peak diastolic velocity ( r = 0.02, p = 0.93). In infants born at or before 35 wk gestation, incidences of both spontaneous closure and indomethacin-induced closure of ductus were similar in both study groups (p > 0.1). Ductal reopening tended to occur more frequently after indomethacin (17%) than after nylidrin (0%) administration ( p = 0.15). These findings indi- The common therapy for inhibiting preterm labor process is administration of P-sympathomimetic agents. However, these drugs have no beneficial effect on perinatal mortality or on the frequency of prolongation of pregnancy to term (1, 2) . In addition, they have several potential cardiovascular side effects. In pregnant women, cases of myocardial ischemia, supraventricular tachycardia, and pulmonary edema have been reported (2, 3) . Cases of myocardial toxicity have been reported in infants of mothers treated with a 0-sympathomimetic agent (4, 5) .
Indomethacin has been recently used as a tocolytic drug. It readily crosses to the placenta (6) and may cause a transient vasoconstriction of the fetal ductus arteriosus (7) . Postnatally, indomethacin is the drug of choice in the treatment of persistent ductus arteriosus (8) .
We have demonstrated that fetal ductus becomes more reactive to indomethacin with increasing gestational age (9) . The primary objective of this study was to further evaluate whether the degree of ductal constriction and especially the occurrence of TR depend on the length of gestation. The secondary objective was to determine whether prenatal exposure to indomethacin decreases the requirements of indomethacin or surgery for treatment of PDA in premature infants.
PATIENTS AND METHODS
A total of 84 pregnant women with threatened premature birth between 22.9 and 34.0 wk gestation were enrolled in the study at the University Central Hospital, Helsinki, Finland (Table 1) . None of the women had pregnancy-induced hypertension. Indomethacin treatment was given to 46 and nylidrin treatment to 38 women for tocolysis. Their 94 offspring, born at 24.7 to 41.6 wk of gestation, were included in the study. The study protocol was approved by the Hospital Ethics Committee.
Of those 84 pregnant women, 48 were randomly and blindly allocated (a sealed envelope) to receive either indomethacin (n = 24) or nylidrin hydrochloride (n = 24). The treatments were identical in appearance, so that each patient received an i.v. infusion containing either nylidrin or placebo and oral capsules containing either indomethacin or placebo (10) . In addition, 36 women were randomized according to the date of birth to receive either indomethacin (odd year number; n = 22) or nylidrin (even year number; n = 14). The dosage of indomethacin (Orion Pharmaceutica, Espoo, Finland) consisted of an initial rectal suppository (100 mg) followed by eight oral capsules (50 mg) at 8-h intervals. Nylidrin (Orion Pharmaceutica) was infused i.v. in physiologic saline with an initial dose of 50 pg/min; this was increased within 30 min to the maintenance dose of 100 to 150 pg/min. Both treatments were administered until cessation of MHz, respectively) was used for examination of the fetal and neonatal heart. The fetal heart was studied once before the therapy, one or two times during the therapy (12 and 24 to 36 h after the start), and one or two times after discontinuation of the therapy (24 or 72 h later). The ultrasound examinations were repeated when indomethacin was used. The ductal arch was obtained either in longitudinal or in short-axis view, depending on the orientation of the fetus. The aortic arch was differentiated from the ductus arteriosus by identification of the aortic arch vessels. The Doppler beam was positioned at the junction of the ductus and descending aorta until V, , , was attained (1 1). The Doppler tracings were accepted when the angle between the Doppler beam and the direction of flow was 15" or less. Ductal PSV and PDV were measured. An average of three beats was used to establish each value. Serial studies demonstrated the change in ductal flow velocity during treatment, but only the examination with the highest flow velocity was used for analysis (1 1).
Evidence of TR was sought from the four-chamber view in each examination. Valve regurgitation was visualized as a holosystolic regurgitant flow by pulsed, continuous-wave, or color Doppler ultrasonography. Fetal heart rate was registered. All studies were recorded on videotape for later playback and analysis.
The patency of ductus arteriosus in the neonates was determined by Doppler ultrasound at 6, 18, 30, and 72 h after birth and thereafter daily until the ductus was closed. In case of a suspicion of ductal reopening, the scan was repeated. To assess the direction of ductal shunting, the pulmonary artery, ductus arteriosus, and aorta were visualized in a high left sternal view. In open ductus, a unidirectional or bidirectional shunting was demonstrated (12) . Hemodynamically significant ductus arteriosus was defined as left to right shunt in the ductus, associated with clinical signs of PDA (hyperdynamic precordium, collapsing pulses, or central pulmonary edema on chest x-ray). The hemodynamically significant PDA was treated with indomethacin, provided that no contraindications were present. The decision to treat the PDA was made by medical staff not involved with the study protocol. Indomethacin was administered i.v. (0.2 mg/kg/ dose) and it was repeated twice (0.1 mg/kg/dose), 12 and 24 h later. After the indomethacin treatment, the ductal patency or closure was confirmed by ultrasound. In case of patency, indomethacin treatment was repeated. After two courses of indomethacin treatment, infants with PDA and congestive cardiac failure underwent surgical ligation.
Pulmonary hypertension was defined as bidirectional ductal shunting or as a suprasystemic pulmonary artery pressure, calculated from tricuspid regurgitant Doppler velocity (in mm Hg), plus assumed right atrial pressure (1 3 The longitudinal changes in ductal velocities were evaluated by the analysis of variance (repeated measurements). The significance of the relationship between the ductal flow velocity and the gestational age during tocolysis was evaluated by regression analysis (Pearson's correlation coefficient). Patency or spontaneous closure of PDA and the frequencies of treatment of PDA (indomethacin, ligation, or both) for the study groups were compared by x2 analysis. The ages at spontaneous closure, ages at first dose of indomethacin, or time interval between first dose and closure of PDA were compared between the two study groups by Mann-Whitney U test. A p value of <0.05 was considered significant.
RESULTS
Characteristics ofpregnancies, fetuses, and neonates. The pregnant women receiving either indomethacin or nylidrin were comparable with each other on the basis of clinical variables listed in the Table 1 . The length of the tocolytic treatment was an average 47 h (range 12 to 72 h). Altogether, seven women needed more than one course of indomethacin treatment. Four women had two courses, two had three courses, and one had five courses of indomethacin. Four of the seven women had multiple pregnancies. Gestational age at birth was significantly higher in indomethacin-treated infants than in nylidrin-treated infants ( p = 0.03). There were three neonatal deaths (one girl and two boys); two in the indomethacin and one in the nylidrin group. All who died were born between 24 and 27 wk and weighed between 680 and 1005 g. The deaths were due to severe RDS (three) accompanied by pulmonary hypertension (one), streptococcus group B sepsis (one), and grade 3 to 4 intraventricular hemorrhage (one).
Ductal jlow velocities in fetuses.
Of the 94 fetuses, 88 were studied using echocardiography. Measurements during tocolytic treatment failed in five fetuses because of maternal discomfort. Altogether, 83 fetuses (49 in the indomethacin group and 34 in the nylidrin group) could be measured reliably. Among them, 103 observations of peak flow velocity values during tocolytic The intrauterine ductal flow velocity values and heart rates before, during, and after treatments are shown in Table 2 . The PSV and PDV were significantly higher during indomethacin treatment than during nylidrin treatment ( p = 0.0001). Altogether, 42 fetuses (86%) in the indomethacin group had ductal constriction (PSV of more than 140 cm/s and PDV of more than 35 cm/s) when studied at a mean age of 29.2 wk (range, 24.0 to 34.0 wk). The mean PSV in these fetuses was 174 cm/s (range, 140 to 255 cm/s), and mean PDV was 63 cm/s (range, 36 to 145 cm/s). Seven fetuses (14%) in the indomethacin group had no evidence of ductal constriction. The mean gestational age of these fetuses was 25.9 wk (range, 24.3 to 28.6 wk); this was significantly less (p = 0.002) than the gestation of the fetuses with ductal constriction. The mean PSV of these fetuses was 123 cm/s (range, 103 to 136 cm/s; p = 0.0001), and mean PDV was 3 1 cm/s (range, 18 to 4 1 cm/s; p = 0.002).
In the nylidrin group, no fetus had ductal constriction. Three fetuses (29 to 33 wk gestation) had a clearly elevated PSV in the ductus during treatment (142 to 145 cm/s). No fetus in this group had a PDV of more than 35 cm/s (range, 12 to 35 cm/s). The mean heart rate during nylidrin administration was significantly higher than during indomethacin administration (155 beatslmin versus 145 beats/min; p = 0.0003).
Ductal flow velocities increased significantly in both groups during tocolytic treatment. In the indomethacin group, the change was significant in both PSV (mean, 56 cm/s; range, 8 to 131 cm/s) and PDV (mean, 33 cm/s; range, 1 to 94 cm/s) ( p = 0.0001, n = 19); whereas, in the nylidrin group, only the PSV increased (mean 16 cm/s; range, 0 to 40 cm/s) ( p = 0.002, n = 13).
The relationship between ductal flow velocities and gestational age in both study groups is presented in Figures 1 and 2 . In the indomethacin group, both PSV and PDV correlated with gestational age (r = 0.54, p = 0.0001, and r = 0.46, p = 0.0001, respectively; Fig. 1) . A less marked relationship was seen in PSV in the nylidrin group (r = 0.35, p = 0.04; Fig. 2 ). There was no detectable change in the PDV as a function of the gestational age in the nylidrin group ( r = 0.02, p = 0.93; Fig. 2) .
TR. Eleven fetuses in the indomethacin group (22%) had TR. All these fetuses had ductal constriction. Gestational age and ductal PSV and PDV tended to be higher in the fetuses with TR than in fetuses without TR (Table 3) . TR resolved within 24 h after treatment in nine fetuses (mean gestational age, 29.3 a 2.8 wk) and within 72 h in two (32.6 and 34.0 wk gestation; p = 0.06). In the nylidrin group, at no time in any fetus was there evidence of TR.
There were three twins with TR. The mothers received indomethacin at 26.3, 26.4, and 29.3 wk gestation. The mean PSV in these fetuses was 162.5 cm/s (range, 147 to 184 cm/s) and mean PDV 46 cm/s (range, 36 to 55 cm/s). One twin (gestation 27.0 wk, birth weight 1005 g) who was delivered during indomethacin treatment died of severe RDS and pulmonary hypertension at the age of 18 h. Autopsy revealed closed ductus.
Closure of ductus arteriosus in neonates. All 94 newborn infants were included in the outcome analysis. The frequencies of the spontaneous closure and of treatment of PDA in the two study groups are shown in Table 4 . In the neonates born after 35 wk gestation (n = 55), there were no significant differences in gestational age ( p = 0.08) or birth weight ( p = 0.26) between the indomethacin or nylidrin groups. In addition, the age of the infants at the time of spontaneous closure was not significantly different between the groups ( p = 0.54). None of these neonates had any treatment for the PDA. Altogether, 39 infants were born at or before 35 wk of gestation (1 7 in the indomethacin group and 22 in the nylidrin group). No detectable difference in gestational age ( p = 0.27), birth weight ( p = 0.31), or incidence of RDS ( p = 0.36) was encountered. The incidence of spontaneous closure of ductus ( p = 0.36) and the age of closure ( p = 0.14) were not significantly different between the groups. Among the infants delivered within 3 d after discontinuation of maternal treatment, there were two cases (one in both groups) with spontaneous closure of ductus before 6 h of age ( p > 0.5).
Nine infants required indomethacin for closure of ductus postnatally (four in the indomethacin group and five in the nylidrin group; p = 0.69). The first dose of indomethacin was given to both groups of infants at similar ages ( p = 0.53), and the PDA closed at similar intervals after the first dose in both groups (p = 0.75). Two neonates received two courses of indomethacin (one in both groups).
Surgical ligation of PDA was performed in three infants who received indomethacin for treatment of preterm labor. In these neonates, the mean gestational age was 26.0 wk (range, 24.7 to 27.9 wk), and the mean birth weight was 790 g (range, 630 to 1020 g). The ligations were performed at 7, 20, and 44 d of age. None of the infants in the nylidrin group were ligated ( p = 0.15).
Ductal reopening was detected in three infants (gestational age, 24.7, 25.4, and 30.0 wk). They all were born less than 3 d after discontinuation of maternal indomethacin treatment. In these infants, ductus was initially closed within 4 d after birth (two spontaneous closures and one after indomethacin treatment). Ductal reopening was evident at 16, 20, and 40 d of age. Ductus was closed with indomethacin in one infant, and two infants required ligation. None of the infants in the nylidrin group had ductal reopening ( p = 0.15).
Pulmonary hypertension in neonates. Three premature neonates had persistent pulmonary hypertension (two in the indomethacin and one in the nylidrin group; p = 0.7). In the indomethacin group, two twins (27.0 wk of gestation) had severe
The fetal ductal constriction is characterized by increased systolic and diastolic ductal flow velocities, resulting in a Doppler wave form similar to that seen postnatally across coarctation of the aorta (1 I). In a previous study (7) , ductal constriction occurred in seven of the 14 fetuses studied. In the present study, the incidence of ductal constriction was 86% in indomethacintreated fetuses and 78% in studies performed during indomethacin treatment. Indomethacin crosses the human placenta easily throughout gestation (6) . The ductal constriction occurred as early as 24.0 wk and as late as 34.0 wk. In addition, PDV in the ductus was clearly elevated (38 cm/s) in a fetus with very early gestational age (22.9 wk), indicating that the ductus was reactive to indomethacin. The mean gestational age of the fetuses with ductal constriction was higher than that of those without constriction. In addition, there was a significant linear positive relationship between the gestational age and PSV or PDV in the ductus arteriosus during indomethacin treatment. These results confirm our earlier findings (9) that the ductus becomes more reactive to indomethacin with increasing gestational age.
A modest increase in PSV in the ductus was evident in fetuses exposed to nylidrin. PDV in the ductus was not increased. Elevated PSV is likely due to an increased flow volume in the right heart (14) . An increased flow through a wide-open ductus shows a Doppler pattern with a rapid decrease after PSV to the baseline and, once again, an increase in diastole and a decrease toward end-diastole. In ductal constriction, flow velocity across the ductus arteriosus slowly decreases from its maximum to enddiastole. Therefore, during nylidrin treatment, the shape of the Doppler wave form is different from that seen during ductal constriction (14) . In this study, a moderate increase in PSV in the ductus with advancing gestational age is in agreement with previous studies (I 5).
In animal studies, acute fetal ductal occlusion imposes a marked increase in the right ventricular afterload, resulting in reversible TR (1 6) . In this study, TR occurred in I I of 49 fetuses treated with indomethacin (22%) and in 11 of 42 fetuses with ductal constriction (26%). TR developed as early as 25.7 wk gestation and as late as 34.0 wk gestation. The mean gestational age of the fetuses with TR tended to be greater than that of those without TR. In addition, the constrictive response of the ductus increased with gestational age. According to these findings, an intensive constriction of the ductus causes pressure and afterload increase in the right ventricle, resulting in TR. In fetuses with very early gestational age, the myocardium and the papillary muscles may not tolerate even a slight pressure increase in the right ventricle caused by ductal constriction.
There are reports of pulmonary hypertension in newborn infants after administration of indomethacin (17, 18) . In the present study, no significant difference in the incidence of pulmonary hypertension between the groups could be found; in three premature infants (two in the indomethacin group and one in the nylidrin group), pulmonary hypertension was associated with severe RDS.
A decreased incidence of PDA after prenatal exposure to indomethacin in preterm babies has been demonstrated (1 9). In the present study, however, the frequencies of both spontaneous closure of PDA and of the requirement of indomethacin for treatment of PDA were similar in both study groups. Ligation of PDA was performed in three infants who were exposed to indomethacin before birth; two of them had ductal reopening. Ductal reopening was found in three of 17 infants (17%): two after primary spontaneous closure and one after successful indomethacin-induced closure. None of the infants in the nylidrin group had ductal reopening. According to these and other findings (20) , the ductus in immature babies maintains its ability to contract and relax after indomethacin treatment.
In conclusion, although indomethacin may have a therapeutic role in specific pregnancies, it has serious hemodynamic side effects that are related to fetal ductal constriction. In view of this study, measurement of ductal flow velocities and evaluation of tricuspid valve function are necessary when indomethacin is administered prenatally especially with increasing gestational age. In premature infants, prenatal administration of indomethacin did not decrease the need for PDA treatment.
